洛铂联合依托泊苷治疗小细胞肺癌的临床疗效.pdf

《洛铂联合依托泊苷治疗小细胞肺癌的临床疗效.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、临床肺科杂志2013年9月第18卷第9期164l洛铂联合依托泊苷治疗小细胞肺癌的临床疗效叶静陆友金赵卉【摘要l目的评价洛铂联合依托泊苷治疗初治小细胞肺癌的疗效和毒副反应，并与同期应用的顺铂联合依托泊苷治疗初治小细胞肺癌的方案相比较。方法分析呼吸内科住院治疗的45例初治小细胞肺癌患者，其中洛铂治疗组25例：洛铂50mS／m，iv，dl，依托泊苷：lomg／m，iv，dl～3；顺铂治疗组2O例：顺铂80ms／m，iv，dl，依托泊苷：lomg／m，iv，dl～3；并对两组患者近期疗效及毒副反应进行比较。结果洛铂组CR8例，PR9例，S

2、D4例，PD4例；顺铂组CR9例，PR7例，SD3例，PD2例；两组总有效率为68％和80％，差异无统计学意义(P=0．805)。全组主要毒性反应为骨髓抑制。顺铂组Ⅲ一Ⅳ度胃肠道反应及脱发明显高于洛铂组，差异有统计学意义(P<0．05)。结论洛铂联合依托泊苷治疗初治小细胞肺癌疗效确切，毒副反应小，与顺铂联合依托泊苷方案相比，疗效相似。【关键词】小细胞肺癌；洛铂；顺铂；依托泊苷Comparisonbetweenetoposidepluscisplatinandetoposidepluslobaplafininthetreatment

3、ofsmall-celllungcancerYE加，LUYou-fin，ZHAOHuiDepartmentofRespiratoryMedwine，theSecondHospitalofAnhuiMed&alU-niversity，Hefei，Anhui230601，China【AbsWad】ObjectiveTocomparetheeficacyandadverseefectsbetweentheregimenofetoposideandcisplatinandtheregi—menofetoposideandlobaplati

4、ninthetreatmentofsmall—celllungcancer．Methods42patientswithsmall—celllungcancerwereran—domlydividedintotwogroups．ThegroupA(n=25)wasgivenlobaplatinat50ms／m，i．vonDay1andetoposideatlOOms／m2，i．vfromDay1toDay3．ThegroupB(n=20)wastreatedwithcisplatinat8Oms／m，i．vonDay1andetop

5、osideat100ms／m，i．vfromDay1toDay3．Eficacyandadverseeffectwerecomparedbetweenthetwogroups．ResultsTherewere8casesofCR．9casesofPR，4casesofSD，and4casesofPDinthegroupA，andtherewere9casesofCR，7casesofPR，3casesofSD，and2casesofPDinthegroupB．Theoverallresponseratewas68％inthegro

6、upAand80％inthegroupB．Therewasnostatisticaldifferenceonthere-sponseratebetweenthetwogroups(P=0．805)．Themainadversereactionincludedbone—mallOWdepression．Theincidenceofm一1vnausea／vomitingandalopeciawashigherinthegroupAthaninthegroupB(P<0．05)．ConclusionTheetoposidepluslob

7、aplatinreg-imenisaneffectiveandlow—toxicitychemotherapyininitialtreatmentofsmall—celllungcancer，whichhasthesimilarcurativeeffectwiththeregimenofetoposideandcisplatin．【Keywords】small—celllungcancer；lobaplatin；cisplatin；etoposide肺癌是我国最常见的恶性肿瘤之一，近年来其发生率及56岁。全部病例均经病理学或组织细

8、胞学确诊的初治患者。病死率上升幅度呈各类恶性肿瘤之首。其中小细胞肺癌其中纤支镜确诊28例；CT引导下经皮肺穿刺术确诊9例；锁(SCLC)在肺癌中所占的比例约为10％一20％。SCLC肿瘤细骨上淋巴结穿刺细胞学确诊3例。分期采用国际肺癌研究协胞倍增时